Skip to main content

Lumito, a company specialising in medical technology for digital pathology, has signed a partnership agreement with Optronic. The new agreement covers final design, industrialisation and production of optical analysis instruments known as WSI (Whole Slide Imaging) scanners.

Man in white shirt and dark jacket smiling at the camera

Mattias Lundin, CEO Lumito

“Optronic is a valuable partner strategically and I look forward to our work together to complete the final design and production start-up of Lumito’s scanner. Through the agreement with Optronic, we have taken an important step towards the planned product launch at the research laboratories at the end of the year,” commented Lumito’s CEO Mattias Lundin when the deal was announced.

Lumito is a spinoff from a research group at Lund University’s Atomic Physics department and Laser Centre. The company’s business is based on a proprietary and patented technology that enables images with greater contrast where unimportant background information is sorted out, making it easier for pathologists to find cancer indications, for example.

The scanner that Optronic will help commercialise will allow pathologists to make digital images of tissues. It can also make images of traditionally stained tissue samples, which is done with haematoxylin staining and immunohistochemistry.

For Optronic, the partnership is a strategically important step.
“We have identified medtech as an interesting segment for us as it is an area where the trend is towards increased use of optical metrology. Further, we already have a number of previous experiences in this area and we are confident that we can meet the requirements and standards that are set in the medtech industry,” says Ulrik Stenbacka, CEO of Optronic.

He also believes that this partnership is just right for Optronic:
“We are stepping into a position where Lumito’s product is being brought to the market, which is a perfect match for our competence profile. Many of our greatest strengths will come to good use in this partnership.”

Intensive work has begun to reach the goal of commercialisation by the end of 2022.
Another important part is about quality assurance of the scanner’s supply chain.
“This is about both logistics and evaluation of suppliers. This is a complex product consisting of many components, some of which are tailored precisely for this purpose. We will help to both create reliability in delivery and find the right cost levels. In a situation where the component market is critical, these things are also vital to a successful product launch,” says Ulrik Stenbacka.

Author Optronic

More posts by Optronic